Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the detailed description of a clinical trial for nintedanib in treating systemic sclerosis associated interstitial lung disease (SSc-ILD), while adding a new EudraCT number and a revision number.SummaryDifference9%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.